April 13th, 2023
Introducing: SmithRx Low Cost Insulin Program
Diabetes is commonly one of the highest drug spend categories for employer groups.
SmithRx is forging new pathways to make insulin more affordable. Starting July 1, 2023, biosimilar insulin products manufactured by Lilly will be preferred on the SmithRx formularies. In the SmithRx pass-through model, all the savings from filling biosimilar insulins are passed along to the employer group.
Lilly is the maker of Humalog and also manufactures lower cost alternatives (i.e. Insulin Lispro) that are interchangeable with the brand products. The SmithRx Low Cost Insulin Program decreases the cost of insulin at the pharmacy for employer groups and applies a savings card to reduce member copays to $35 or less for a 30 day supply for Lilly insulin products. Through this program, the cost of insulin is the lesser of the member’s standard copay or $35 for a month’s supply.
The lowest cost insulin for mealtime is Insulin Lispro 100 units/mL (biosimilar for Humalog) and long acting once daily is Rezvoglar (biosimilar for Lantus). These lower cost biosimilar insulins can be filled at any pharmacy within the SmithRx network.
Interested in learning more about how your clients can benefit from SmithRx's Low Cost Insulin or our other Connect programs? Get in touch!
Already a SmithRx client and want to learn more? Our Account Managers are happy to hear from you.
Other Recent Posts
Introducing: SmithRx Low Cost Insulin Program
Diabetes is commonly one of the highest drug spend categories for employer groups. SmithRx is forging new pathways to make insulin more affordable. Starting July 1, 2023, biosimilar insulin products manufactured by Lilly will be preferred on the SmithRx formularies. In the SmithRx pass-through model, all the savings from filling biosimilar insulins are passed along… Continue reading Introducing: SmithRx Low Cost Insulin Program
Same drug, two different prices? Legacy PBMs play games with Humira biosimilars
On January 31, 2023, Amgen released Amjevita, the first biosimilar for AbbVie’s Humira. This ended AbbVie’s 20-year monopoly for a drug with a sticker price of $90,000/year, and finally introduced competition to bring down drug costs. While Amjevita is cheaper than Humira, its pricing structure is strange: it is offered at two different price points.… Continue reading Same drug, two different prices? Legacy PBMs play games with Humira biosimilars
SmithRx and Mark Cuban Cost Plus Pharmacy team up to reduce prescription drug costs
Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) has joined the SmithRx pharmacy network! SmithRx is one of the few pharmacy benefit cards that can be used at Cost Plus Drugs. Members can simply enter their SmithRx insurance information when creating an account at CostPlusDrugs.com. This expands access to more affordable prescription drugs for… Continue reading SmithRx and Mark Cuban Cost Plus Pharmacy team up to reduce prescription drug costs
